The medication is indicated for on-demand treatment and control of bleeding episodes.
Update: Shire has issued a new statement regarding the injunction.
In the past few weeks, we have received many inquiries regarding the scope of the injunction Shire is seeking in its lawsuit against Genentech/Roche.
Medscape recently launched a new education opportunity for healthcare providers.
BioMarin provided a series of updates on their investigational hemophilia A gene therapy candidate valoctocogene roxaparvovec.
The FDA has lifted a hold on clinical studies involving the investigational therapy fitusiran.
This agreement allows Shire to conduct research on the use of Rani Pill™ technology for the oral delivery of factor VIII therapy for patients with hemophilia A.
Spark provided clinical trial updates on the company’s investigational gene therapies for hemophilia A and B, SPK-8011 and SPK-9001.
Genentech recently reported results from the phase III HAVEN 3 study, which showed that the prophylactic use of HEMLIBRA® led to significantly reduced bleeds in adult and adolescent patients with h
Alnylam is developing the therapy to treat patients with hemophilia A and B, both with and without inhibitors.
People who used the therapy for nearly three years saw regular improvements in their joint health.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car